Key factors
sym | BLRX |
exch | US |
MCap | 51.16M |
Beta | 0.927 |
EPS | -0.9 |
Div date | 0000-00-00 |
Yesterday
sym | BLRX |
exch | US |
close | 0.613 |
50 Day MA | 1.067 |
200 Day MA | 1.442 |
52 Week High | 2.53 |
52 Week Low | 0.61 |
Target Price | 13.75 |
Market Cap Mln | 51.16 |
Share statistics
Shares Outstanding | 79.93M |
Shares Float | 989.89M |
Percent Institutions | 1.437 |
PercentInsiders | 8.543 |
SharesShort | 591.44K |
Short Ratio | 1.74 |
Shares Short Prior Month | 324.64K |
Short Percent | 0.449 |
Income
Revenue TTM | 4800.0K |
Revenue Per Share TTM | 0.075 |
EBITDA | -42.1M |
Diluted Eps TTM | -0.9 |
earning
Operating Margin TTM | -2.47 |
PEGRatio | 0.2 |
EPS Estimate Current Quarter | -0.26 |
EPS Estimate Current Year | -1.03 |
EPS Estimate Next Year | -0.93 |
Earnings Share | -0.9 |
Dividend
Dividend Date | 2019-07-15 |
Last Split Date | 2019-07-15 |
Last Split Factor | 1:15 |
business
Enterprise Value Ebitda | -0.44 |
Enterprise Value Revenue | 5.292 |
Book Value /share | 0.012 |
Price Book MRQ | 4.333 |
Price Sales TTM | 11.93 |
ReturnOnAssetsTTM | -0.38 |
ReturnOnEquityTTM | -1.89 |
Sector
Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
Gic Industry | Biotechnology |
Gic Sector | Health Care |
Gic Sub Industry | Biotechnology |
Industry | Biotechnology |
Sector | Healthcare |
Codes
ISIN | US09071M2052 |
Code | BLRX |
CUSIP | 09071M205 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NASDAQ |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2024-04-19 |
Home Category | ADR |
info
Fiscal Year End | December |
Full Time Employees | 79.0 |
IPODate | 2011-07-25 |
International Domestic | International Domestic |
MostRecent Quarter | 2023-12-31 |
Contact
Name | BioLineRx Ltd |
Address | Modi?in Technology Park, Hevel Modi'in, Israel, 7177871 |
Country Name | USA |
Phone | 972 8 642 9100 |
Web URL | https://www.biolinerx.com |
Logo URL | /img/logos/US/BLRX.png |
BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in, Israel.